Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
Date: February 7, 2022
Issue #:
1643Summary:
Lonapegsomatropin-tcgd (Skytrofa– Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for
once-weekly subcutaneous (SC) treatment of growth
failure due to inadequate secretion of endogenous
growth hormone in children≥1 year old who weigh≥11.5 kg. It is the first once-weekly rhGH product to be
approved in the US; other available rhGH formulations
are administered more frequently.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Genotropin Growth hormone Humatrope lonapegsomatropin Norditropin Nutropin Omnitrope Saizen Skytrofa Zomacton Source Type: research